Kabra Drugs — 360° view

Kabra Drugs, a company in the Pharmaceuticals industry, reported revenue of ₹32 crore and net profit of ₹1.92 crore for the September 2026 quarter.

Kabra Drugs (BSE: KABRADG) closed at ₹18.89 on 20 Nov 2026, down 26.4% over the past year. Its market capitalisation is ₹45 crore and it trades at 5.8 times earnings.

Share price
₹18.89 (20 Nov 2026)
Market cap
₹45 Cr (20 Nov 2026)
P/E
5.78 (20 Nov 2026)
Revenue
₹32 Cr (September 2026 quarter)
Net profit
₹2 Cr (September 2026 quarter)
ROCE
20.8% (FY26)
ROE
18.3% (FY26)
Book value
₹14.2 (FY26)
Dividend yield
0.00% (FY26)
52-week high / low
₹35.52 / ₹15.25 (20 Nov 2026)
1-year return
-26.4% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
BSE: KABRADG

Incorporated in 1989, Kabra Drugs Ltd deals in pharmaceutical products, biological API’s and biochemicals.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.